









Markets
/
Stocks
/
nasdaq-ahg
/

Akso Health Group

AHG



View Detailed Chart

1.390USD

-0.020-1.42%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

767.09MMarket Cap

LossP/E TTM



Akso Health Group

1.390

-0.020-1.42%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.42%

5 Days

+7.75%

1 Month

-7.33%

6 Months

+14.88%

Year to Date

+2.21%

1 Year

+24.11%

View Detailed Chart

TradingKey Stock Score of Akso Health Group

Currency: USD Updated: 2025-12-26

Key Insights

Akso Health Group's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 243/482 in the Software & IT Services industry.Institutional ownership is very low.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Akso Health Group's Score

Industry at a Glance

Industry Ranking

243 / 482

Overall Ranking

423 / 4563

Industry

Software & IT Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Akso Health Group Highlights

StrengthsRisks

Akso Health Group, formerly Xiaobai Maimai Inc, is a China-based company mainly engaged in e-commerce business. The Company provides services through the Xiaobai Maimai application (APP), a one-stop e-commerce platform. The Company provides products covering food and beverage, wine, cosmetic products, fashion and apparel, entertainment, houseware, home appliances and others. The Company is also engaged in social e-commerce platform business, cancer therapy and radiotherapy oncology service provider business, and the sale of coronavirus disease 2019 (COVID-19) Rapid Antigen Tests.

Growing

The company is in a growing phase, with the latest annual income totaling USD 14.78M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 14.78M.

Undervalued

The company’s latest PE is -2.96, at a low 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 129.20K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.80.